Retatrutide showed ~24% mean body-weight reduction at 48 weeks in TRIUMPH-4 versus tirzepatide's ~22.5% in SURMOUNT — a 1.5–2 point delta. Retatrutide targets three receptors (GLP-1, GIP, glucagon); tirzepatide two (GLP-1, GIP). Retatrutide is Phase 3, not FDA-approved as of May 2026; tirzepatide is FDA-approved (Zepbound 2023, Mounjaro 2022) with compounded availability contracting under PCAC restrictions.
Same lab, different mechanism
Both compounds come out of Eli Lilly's metabolic-disease research pipeline. Tirzepatide is the older, FDA-approved compound; retatrutide is the next-generation candidate with the TRIUMPH Phase 3 program reading out across 2025–2026.
The mechanism difference that matters: tirzepatide hits two receptors — GLP-1 and GIP. Retatrutide hits three — GLP-1, GIP, and glucagon. The third receptor is what produces both the larger weight-loss effect and the distinct side-effect profile.
Why glucagon matters mechanistically: GLP-1 and GIP receptor activity primarily modulate appetite, gastric emptying, and insulin secretion. Glucagon-receptor activity adds energy-expenditure modulation — the body burns more, not just eats less. This is the structural reason the retatrutide weight-loss curve does not plateau at the same point as the GLP-1-only and GLP-1+GIP compounds.
Trial outcomes — Phase 2 to Phase 3
The Phase 2 retatrutide readout (Jastreboff et al., NEJM 2023) showed 24% mean body-weight reduction at 48 weeks at the highest tested dose. The TRIUMPH Phase 3 program has held the magnitude: recent published TRIUMPH readouts confirm ~24% at the 48-week mark and continued downward slope past that point in the open-label-extension data.
| Compound | Mechanism | Peak weight loss (Phase 3, 48-week, top dose) | Approval status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 mono-agonist | ~15% | FDA-approved, 2021 |
| Tirzepatide (Zepbound) | GLP-1 + GIP dual-agonist | ~21% | FDA-approved, 2023 |
| Retatrutide | GLP-1 + GIP + glucagon triple-agonist | ~24% (TRIUMPH Phase 3) | Phase 3 — FDA submission expected 2026 |
Two structural observations on the Phase 3 readout (covered in detail in our TRIUMPH-4 results read):
The retatrutide weight-loss curve continues sloping past 48 weeks. This is mechanistically consistent with glucagon-receptor activity adding sustained energy-expenditure modulation, and the open-label-extension data through 88 weeks supports it. Tirzepatide SURMOUNT readouts show flatter slopes by the 40-week mark.
The retatrutide side-effect profile adds a heart-rate signal. GI side effects (nausea, vomiting, dose-titration tolerability) are broadly comparable to the GLP-1 mono- and dual-agonists. The glucagon-receptor activity introduces a heart-rate elevation signal of 1–3 bpm above baseline across the reported populations — modest in magnitude but distinct from tirzepatide and semaglutide. The TRIUMPH-5 cardiovascular-outcomes trial is the readout that will characterize this dimension at scale.
Regulatory state — May 2026
The two compounds sit in materially different regulatory positions as of May 2026, and the difference matters for any reading of the literature.
Tirzepatide. FDA-approved as Zepbound for chronic weight management (2023) and as Mounjaro for type 2 diabetes (2022). Brand product available through standard prescription channels. Compounded tirzepatide is approaching closure following the October 2024 PCAC vote and the April 2026 PCAC reaffirmation (see our 503A and PCAC analysis) — compounded availability through telehealth providers has been contracting through 2025–2026. The legal access route is now predominantly brand prescription.
Retatrutide. Not FDA-approved. The Eli Lilly investor communications through Q1 2026 indicated a 2026 FDA submission target. Standard-review approval would land in 2027; priority-review approval (less likely) could come in late 2026. Until approval, retatrutide is not in the legal prescription channel, and it does not enter the 503A compounding pathway on approval (compounded retatrutide is not eligible).
This regulatory asymmetry is the primary buyer-relevant difference between the two compounds in May 2026. The literature on the molecules is increasingly detailed; the legal access difference is what shapes the practical decision.
What the buyer-relevant comparison looks like
A clean side-by-side, focused on the dimensions that move the buyer decision:
| Dimension | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism receptors | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Phase 3 weight-loss peak | ~21% | ~24% |
| Curve slope at 48 weeks | Plateauing | Continued decline |
| Side-effect profile | GLP-1 class typical | + heart-rate elevation signal |
| Legal access (May 2026) | Brand prescription (Zepbound/Mounjaro) | None — Phase 3 only |
| Compounded availability | Closing (PCAC restrictions) | Not eligible |
| Cross-vendor research-peptide quality data | Wide, multi-year | Narrower, higher variance |
The cross-vendor quality data dimension is meaningful. The Janoshik 7,164-tests purity analysis showed that retatrutide research-peptide samples had higher purity variance than tirzepatide and semaglutide samples across the same period. The 37 failed retatrutide samples we documented in the Peptide Sciences postmortem are part of this pattern — the retatrutide research-peptide market has been the quality-collapse-prone segment of the cycle.
The literature — what's confidently known versus pending
Confidently known about tirzepatide. Multi-year Phase 3 data, extensive post-approval cardiovascular and metabolic outcome data (SURPASS, SURMOUNT trial families), pharmacokinetic and pharmacodynamic characterization across populations, well-characterized dose-titration and tolerability profiles. The compound is thoroughly in the published literature.
Confidently known about retatrutide as of May 2026. Phase 2 data (NEJM 2023) and Phase 3 TRIUMPH-1 through TRIUMPH-3 readouts are published. TRIUMPH-4 has interim readouts available. Pharmacokinetic characterization is solid. The 48-week weight-loss data is well-characterized.
Pending for retatrutide. Long-term durability data beyond 88 weeks is not yet published. Cardiovascular outcomes superiority (TRIUMPH-5) is not yet published. Special populations (pediatric, hepatic impairment, pregnancy) are not covered by the published TRIUMPH program. These are typical Phase-3-to-post-approval gaps and will fill in over 2026–2028.
What this means for the buyer
We do not link to or recommend research-peptide vendors for either compound in this article, but the practical considerations a buyer should hold in mind differ between the two.
For tirzepatide, the cleanest path is the brand prescription channel where eligible. The compounded telehealth channel is closing and the research-peptide channel sits outside the legal access framework regardless of vendor quality. The cross-vendor quality data is favorable on tirzepatide research-peptide samples relative to retatrutide, but that is a comparative observation, not a recommendation.
For retatrutide, no current legal access channel exists for human use outside trial enrollment. The TRIUMPH program enrollment windows have closed for most sites; successor trials may open. The research-peptide channel for retatrutide carries the highest purity-variance signal in the current cycle and is the segment of the market that drove the most recent vendor closures.
What we read
The published Phase 2 retatrutide data (Jastreboff et al., NEJM 2023); the TRIUMPH Phase 3 readouts published through April 2026; the SURMOUNT and SURPASS tirzepatide trial families; the FDA approval documents for tirzepatide (Mounjaro 2022, Zepbound 2023); the publicly-posted PCAC meeting minutes for October 2024 and April 2026; and the Eli Lilly investor presentations covering the retatrutide program timeline. We did not access non-public FDA briefing materials or paywalled sources beyond the cited publications.
Sources
- Jastreboff et al., NEJM 2023 — Phase 2 retatrutide
- SURMOUNT-1 — tirzepatide Phase 3 weight management
- TRIUMPH program — ClinicalTrials.gov NCT entries — search by NCT05882045, NCT05952713, NCT05882187, NCT05996731
- FDA approval documents — Mounjaro and Zepbound
- FDA PCAC meeting materials
- Internal: TRIUMPH-4 Phase 3 retatrutide results, 503A and PCAC compounding analysis, Janoshik 7,164-tests purity analysis, Peptide Sciences postmortem